Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis
- 1 July 2011
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (11) , 1633-1646
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing CountriesVaccine, 2008
- Cost-effectiveness of primarily human papillomavirus–based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of HealthInternational Journal of Technology Assessment in Health Care, 2008
- Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 VaccinationJNCI: Journal of the National Cancer Institute, 2008
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)JNCI: Journal of the National Cancer Institute, 2006
- Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and ItalyJNCI: Journal of the National Cancer Institute, 2005
- Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patientsBritish Journal of Cancer, 2003
- HPV testing in primary screening of older womenBritish Journal of Cancer, 1999